Filing Flows › ImmunityBio (IBRX) › Q4 2024
ImmunityBio (IBRX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 3, 2025
ImmunityBio (IBRX) reported revenue of $7.6M for the fourth quarter 2024 (Q4 2024), up 54-fold from a year earlier and +24% from the quarter before. Operating margin was -919.0%, net loss $59.2M (783.6% of revenue).
ImmunityBio, Q4 2024: revenue $7.6M (54× year over year), operating margin -919.0%, net loss $59.2M, operating cash flow −$85.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.6M | +24% | 54× |
| Operating profit | −$69.4M | — | — |
| Net earnings | −$59.2M | — | — |
| Operating cash flow | −$85.1M | — | — |
What changed
Revenue was $7.6M in Q4 2024, up 5333% year over year and up 24% from the previous quarter. Product revenue, net was the largest line at 95% of revenue.
Operating costs exceeded revenue by $69.4M, an operating margin of -919.0%. Total costs fell 10% while revenue rose 5333%. The fastest-growing cost line was SG&A (+26%). The quarter ended with a net loss of $59.2M, narrower than the previous quarter's $85.8M loss. Minority interests bore $17K of it: to shareholders the quarter was a loss of $59.2M.
Operating cash flow was −$85.1M. Non-cash charges added back $4.1M of depreciation and amortization and $9.0M of share-based compensation. Working capital and other items used $39.1M. Capital expenditures of $2.1M exceeded it, leaving free cash flow of −$87.3M.
Questions
What was ImmunityBio's revenue in the fourth quarter 2024?
ImmunityBio (IBRX) reported revenue of $7.6M for the fourth quarter 2024 (Q4 2024), up 54-fold from a year earlier and +24% from the quarter before.
Was ImmunityBio profitable in the fourth quarter 2024?
Operating loss was $69.4M (-919.0% of revenue) and net loss $59.2M.
Source: ImmunityBio 10-K on SEC EDGAR.